Takeaways: Health Canada’s acceptance of Knight Therapeutics’ New Drug Submission for Gemtesa (vibegron) moves the therapy closer to potential approval in Canada for adults with overactive bladd...
Bayer’s LYNKUET (elinzanetant) receives expanded authorization in Canada for breast cancer-related vasomotor symptoms Bayer Canada announced that Health Canada has expanded the market authorizat...
Takeaways: Knight Therapeutics’ Canadian launch of WYNZORA strengthens its dermatology portfolio and marks the commercialization of a product it inherited through the Paladin acquisition. The launch a...
